All Articles

Among adults who have had a documented substance overdose, those who started on a GLP-1 had a 39% lower risk of a repeat overdose within three years of their overdose compared to patients who were never prescribed a GLP-1. Patients who started and later discontinued a GLP-1 still had a 20% lower risk than patients who never used a GLP-1.

Among adults aged 40–79 with stage 1 hypertension, treatment eligibility rose modestly from 45.2% under the 2017 guideline to 47.0% under the 2025 guideline. Overall, 3.2% of patients would be treated differently under the new guideline (2.5% gained eligibility, 0.7% lost eligibility).

Among adult patients living in states that have legalized sports betting, the quarterly rate of diagnosed gambling disorder rose from 3.0 per 100,000 patients in Q1 2018 to 4.8 per 100,000 in Q1 2026, around a 61% increase.

Based on colorectal cancer detection rates among more than 3 million screening-eligible adults, our model estimates that at age 40 approximately 111 cancers would be detected per 100,000 screenings, compared with 159 per 100,000 screenings at age 45, the current recommended starting age. Based on the model, this equates to nearly 44% more 40-year-olds needing to be screened to detect one colorectal cancer (CRC) case compared to the number of 45-year-olds who would need to be screened.

At 15 months post-treatment, 12.5% of bariatric surgery patients had a new diagnosis of nutritional or iron-deficiency anemia, compared to 4.6% of GLP-1 patients and 3.8% of patients on other weight-loss medications.

The share of outpatient encounters with a systemic antibiotic prescription fell from 10.4% pre-pandemic to 8.0% during the pandemic and partially returned to pre-pandemic levels at 9.1% post-pandemic.

Three months after stopping a GLP-1, 40% of patients had further improved their HbA1c compared to when they discontinued the GLP-1, 48% kept some of their improvement, and just 12% had a worse HbA1c compared to their pre-GLP-1 level.

Scarlet fever diagnoses among pediatric patients dropped sharply during the COVID-19 pandemic and then surged well above pre-pandemic levels, peaking around 47 per 100,000 pediatric patients who had a visit in Q1 2023 and Q1 2024, nearly double the pre-pandemic seasonal peak of 24 per 100,000 in Q1 2019. By Q1 2025, the peak was down to 18.9 per 100,000.

Two new data trackers from Epic Research now provide quarterly snapshots of GLP-1 use and BMI distribution in the U.S. adult population.

Most patients who lost weight before hip or knee replacement had a higher likelihood of surgical site infection and mechanical failure than patients in the same starting BMI class whose weight remained stable. For infection, the likelihood increased with each level of loss, reaching more than six times as likely among overweight patients who lost 20% or more before knee replacement.

Patients who received a short-term opioid prescription within seven days of a hip replacement surgery had a slightly higher proportion of top-tier functional scores at three months (69.8%) compared to those who did not receive opioids (59.3%).

The proportion of primary care encounters with low-dose aspirin on the medication list fell by more than half, from a peak of 7.4% in mid-2018 to 3.2% by the end of 2025, among patients without a history that warrants low-dose aspirin for secondary prevention. The decline was observed across all demographic subgroups. Adults aged 80+ still had the highest prevalence at 5.7%.

Patients prescribed multiple doses per day of ACE inhibitors, ARBs, or calcium channel blockers were less likely to achieve blood pressure control compared to those prescribed once-daily regimens of the same medication classes.

In January 2017, 30.0% of RSV encounters resulted in a hospitalization or ICU admission. By January 2026, that share had fallen to 15.6%, while the proportion managed in emergency departments grew from 29.4% to 45.0%. The share handled in office visits remained stable at around 40%.

Patients who received the at-home nasal influenza vaccine in the 2025/2026 influenza season had a 37.4% lower likelihood of post-vaccination influenza infection compared to those who received the same nasal vaccine in a clinic, after accounting for other factors.

Among adults with type 2 diabetes, osteoporosis risk was lower for patients prescribed a GLP-1 than for patients who were not prescribed a GLP-1, when compared to a baseline of stable-weight patients who were not prescribed a GLP-1.

The 12-month average rate of emergency department (ED) visits for overdoses of all types declined from a peak of 946 per 100,000 ED visits in March 2021 to 634 per 100,000 ED visits in November 2025, falling below pre-COVID-19 pandemic levels. Testing for fentanyl in these encounters more than quadrupled over this period, from 5% of encounters to 28% of encounters.

Peak influenza visit rates for children were up to 90% higher in 2025 than the 2023–24 season. Adults aged 65 and older saw a 56% increase in peak influenza visit rates compared to the 2023–24 season, while rates for adults aged 50–64 remained essentially unchanged.

Among adults aged 45 to 64 who were diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD), those with a non-obese BMI (below 30) were skewed just below the obese BMI threshold with more than 80% having an overweight BMI (25.0–29.9).

Telehealth use in primary care decreased from pandemic-era highs through mid-2023 and has remained relatively stable at around 6 to 7% of encounters since then.